Spencer: A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma
Study Details
Study Description
Brief Summary
This is a multicenter, Phase 1/2, First-In-Human study to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EO2401 in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1/Phase 2 |
Detailed Description
EO2401 is an innovative cancer peptide therapeutic vaccine based on the homologies between Tumor Associated Antigens and microbiome-derived peptides that will be administered in combination with nivolumab to generate preliminary safety and efficacy data in patients with Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: 5-cohort study design Cohort 1:3-by-3 design of EO2401 in combination with nivolumab at standard dose. Three to 12 evaluable patients with adrenal carcinoma or progressive malignant pheochromocytoma/paraganglioma will be included depending on the safety profile of the administered treatments. Cohorts 2A (previously treated patients) and 2B (previously untreated patients): evaluation of EO2401 at the recommended dose found in Cohort 1 in combination with nivolumab in 30 evaluable patients (15 each for Cohorts 2A and 2B) with adrenal carcinoma. Cohorts 3A (previously treated patients) and 3B (previously untreated patients) : evaluation of EO2401 at the recommended dose found in Cohort 1 in combination with nivolumab in 30 evaluable patients (15 each for Cohorts 3A and 3B) with progressive malignant pheochromocytoma/paraganglioma. |
Biological: EO2401
Multiple dose of EO2041 in combination with nivolumab
|
Outcome Measures
Primary Outcome Measures
- Adverse events assessment [Up to 24 months]
Incidences of adverse events(AEs), treatment-emergent AEs (TEAEs), Serious Adverse Events ( SAEs), deaths, and laboratory abnormalities using the National Cancer Institute-Common Terminology Criteria for AEs (NCI-CTCAE) v5.0.
Secondary Outcome Measures
- Evaluation of survival [From end of treatment to at least 24 months after last patient enrollment]
Overall survival, defined as the time interval from the date of first study treatment administration to the date of death due to any cause
- Assessment of the immunogenicity [Up to 24 months]
Assessment of the immunogenicity of the 4 components that compose EO2401 Immunogenicity will be assessed by Interferon-γ ELISpot
Eligibility Criteria
Criteria
Main Inclusion Criteria:
-
For inclusion in Cohort 1 patients should have adrenocortical carcinoma(ACC), or malignant pheochromocytoma/paraganglioma (MPP), as defined below for Cohorts 2A and 3A.
-
For inclusion in Cohorts 2A and 2B patients should have histologically confirmed (at primary diagnosis) unresectable locally advanced or metastatic adrenocortical carcinoma.
-
For inclusion in Cohorts 3A and 3B patients should have histologically confirmed (at primary diagnosis) unresectable malignant (defined as metastatic disease, i.e. presence of chromaffin tissue in non-chromaffin organs) pheochromocytoma/paraganglioma, and RECIST defined progression should have been documented during a maximum of an 18-months period.
-
Patients with an age ≥ 18 years old.
-
Patients who are human leukocyte antigen (HLA)-A2 positive.
-
Patients with an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
-
Patients with a life expectancy > 4 months as judged by their treating physician.
-
Patients with at least one measurable lesion according to RECIST 1.1.
-
Males or non-pregnant, non-lactating, females.
-
Patients willing and able to comply with the scheduled visits, treatment plan, laboratory tests, and other study procedures indicated in the protocol.
-
Patients having received the information sheet and who have provided written informed consent prior to any study-related procedures.
Main Exclusion Criteria:
-
Patients treated with dexamethasone > 2 mg/day or equivalent (i.e. 13 mg/day of prednisone, or 53 mg/day of hydrocortisone) within 14 days before the first EO2401 administration, unless required to treat an adverse event.
-
Patients with prior treatment with immune check-point inhibitors
-
Patients with prior exposure to EO2401.
-
Patients treated with immunotherapy (meaning immunostimulatory or immunosuppressive therapy; beside excluded, or allowed, compounds per other inclusion/exclusion criteria specifications), radionuclide therapy, radiotherapy, cytoreductive therapy, or received treatment with any other investigational agent within 28 days before the first EO2401 administration.
-
Patients with ACC with more than three organs involved by disease, combined with unresectable primary tumor.
-
Patients with ACC and uncontrolled hormonal secretion (according to the judgement of the treating physician).
-
Patients with MPP and uncontrolled blood pressure (according to the judgement of the treating physician).
-
Patients with abnormal laboratory values.
-
Patients with persistent Grade 3 or 4 toxicities.
-
Uncontrolled central nervous system (CNS) metastasis.
-
Other malignancy or prior malignancy with a disease-free interval of less than 3 years
-
Patients with clinically significant disease.
-
Patients with suspected autoimmune or active autoimmune disorder or known history of an autoimmune neurologic condition (e.g. Guillain-Barré syndrome).
-
Patients with history of solid organ transplantation or hematopoietic stem cell transplantation.
-
Patients with history or known presence of tuberculosis.
-
Pregnant and breastfeeding patients.
-
Patients with history or presence of human immunodeficiency virus and/or potentially active hepatitis B virus/hepatitis C virus infection.
-
Patients who have received live or attenuated vaccine therapy used for prevention of infectious diseases including seasonal (influenza) vaccinations within 4 weeks of the first dose of study drug.
-
Patients with a history of hypersensitivity to any excipient present in the pharmaceutical forms of the study treatments.
-
Patients treated with herbal remedies with immunostimulating properties or known to potentially interfere with major organ function.
-
Patients with known ongoing drug and alcohol abuse.
-
Patients with known or underlying medical or psychiatric condition that, in the Investigator's opinion, would make the administration of study drug hazardous to the patient or obscure the interpretation of toxicity determination or AEs.
-
Patients deprived of their liberty, under protective custody, or guardship.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | MD Anderson Cancer Center | Houston | Texas | United States | 77030 |
| 2 | Rigshospitalet | Copenhagen | Denmark | 2100 | |
| 3 | Centre Léon Bérard | Lyon | France | 69008 | |
| 4 | Institut Gustave Roussy | Villejuif | France | 94800 | |
| 5 | Lmu Klinikum | München | Germany | ||
| 6 | Universitätsklinikum Würzburg | Würzburg | Germany | 97080 | |
| 7 | Azienda Ospedaliera Spedali Civili | Brescia | Italy | 25121 | |
| 8 | Máxima Medisch Centrum | Eindhoven | Netherlands | 5631 | |
| 9 | Hospital Universitari Vall d'Hebron | Barcelona | Spain | 08035 | |
| 10 | Karolinska University Hospital | Stockholm | Sweden | 17176 |
Sponsors and Collaborators
- Enterome
Investigators
- Study Director: Jan Fagerberg, Enterome
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- EOADR1-19